Coronary artery calcium (CAC) is a highly specific feature of coronary atherosclerosis. On the basis of single-center and multicenter clinical and population-based studies with short-term and long-term outcomes data (up to 15-year followup), CAC scoring has emerged as a widely available, consistent, and reproducible means of assessing risk for major cardiovascular outcomes, especially useful in asymptomatic people for planning primary prevention interventions such as statins and aspirin. CAC testing in asymptomatic populations is cost effective across a broad range of baseline risk. This review summarizes evidence concerning CAC, including its pathobiology, modalities for detection, predictive role, use in prediction scoring algorithms, CAC progression, evidence that CAC changes the clinical approach to the patient and patient behavior, novel applications of CAC, future directions in scoring CAC scans, and new CAC guidelines. (J Am Coll Cardiol 2018;72:434-47)
C oronary artery calcium (CAC), a highly specific feature of coronary atherosclerosis (1) , is one of the most thoroughly studied and widely available tests in cardiovascular medicine.
Following important single-center and clinical registry studies, large long-term population-based observational studies were launched in the United States (2, 3) , Germany (4) , and the Netherlands (5) in the late 1990s and early 2000s that have produced consistent, reproducible, and convincing evidence of a strong association between CAC (6) and major cardiovascular outcomes in asymptomatic people. Clinical practice guidelines in the United States (7) and Europe (8) consider CAC scoring to be a potentially useful way of improving cardiovascular risk assessment in asymptomatic people and serving as a guide for initiating or deferring preventive therapies. Costeffectiveness analyses (9) (10) (11) (12) (13) (14) have concluded that CAC testing is cost effective in asymptomatic popula-
tions. Yet such application of CAC scoring in asymptomatic people is still sometimes regarded as experimental or unproven by many health insurance companies in the United States (15).
The purpose of this review is to summarize the evidence concerning CAC, with emphasis on asymptomatic patients, including its pathobiology, modalities for detection, predictive role, use in prediction scoring algorithms, CAC progression, evidence that CAC changes the clinical approach to the patient and patient behavior, novel applications of CAC, and future directions in scoring CAC scans.
PATHOBIOLOGY OF CORONARY ARTERY CALCIFICATION
Vascular calcification was accepted until recently as an inevitable result of aging, and the development of CAC was considered a passive process. The development of CAC is now understood to be an active pathogenic process that is not inevitable, and mechanisms that underlie vascular calcification have been identified. Ectopic bone production, a common feature of atherosclerosis, is the basis for coronary artery calcification (16) . Developmental, inflammatory, and metabolic factors all influence the process.
Master transcription factors, such as Msx2, Runx2, Osterix, and Sox9, have been implicated in vascular calcification, as have potent osteogenic differentiation factors, such as bone morphogenetic proteins 2 and 4. Matrix Gla protein is an inhibitor of bone morphogenetic protein and is highly expressed in calcified human arteries (17) . Expression of both proand antiosteogenic factors in CAC highlights the extensive regulation of this process.
Inflammation, propagated by apolipoproteins and oxidized phospholipids in the artery wall, is critical to the development of both atherosclerosis and vascular calcification (18, 19) . Several mediators associated with oxidative stress are implicated in calcification, and oxidative stress may be a key link between inflammation and vascular calcification (20) . Lipid oxidation leads to pro-osteogenic mediators, such as minimally modified low-density lipoprotein and oxidized phospholipids (20) .
Hyperlipidemia likely has both direct and indirect effects on vascular calcification (21) . Glucose can directly promote vascular cell calcification (22) , and insulin can inhibit it (23) . Adipose-derived factors affect calcification, with leptin promoting (24) and adiponectin inhibiting (25) vascular calcification.
MODALITIES FOR DETECTION OF CAC
Early studies of CAC used chest radiography, fluoroscopy, or digital subtraction fluoroscopy (26) and began to show the potential value of CAC in predicting the presence of obstructive coronary artery disease (CAD) (27) , as well as future coronary events (28) (29) (30) (31) 
EARLY STUDIES OF CAC, CORONARY PLAQUE, AND CLINICAL CAD
Pathological studies demonstrated a strong correlation between the presence of coronary calcium and
CAD. An early focus of CAC testing was to compare results to invasive angiography, to establish the sensitivity and specificity to detect obstructive CAD.
Sensitivity for obstructive CAD ranges from 88% to 100% (31, (35) (36) (37) . With high sensitivities for disease, a negative test result has a very low probability of being associated with obstructive CAD, with negative predictive values approaching 100% (38, 39) .
CAC quantification was found to be an excellent anatomic measure of atherosclerotic plaque burden (36, 40) . Sangiorgi et al. (40) showed a significant association between coronary calcification area and plaque volume, compared with no association between coronary calcification and lumen area. Rumberger et al. (36) conducted a histopathologic study of coronary arteries from autopsy hearts that were dissected, straightened, and scanned with EBCT in 3-mm contiguous increments. CAC and coronary artery plaque areas were highly correlated for the hearts as a whole, for individual coronary arteries, and for individual coronary artery segments ( Figure 1 ).
Studies of intracoronary ultrasound have also
confirmed a direct association of the CAC score with the location and extent of atherosclerotic plaques in vivo (41) . 
FINDINGS FROM MAJOR POPULATION-BASED COHORT STUDIES
Findings from population-based cohort studies are presented in Table 1 . On the basis of similar designs and study protocols, the results of the MESA and HNR study cohorts were compared, including 2,220 and 3,126 participants, Imaging of the heart, vasculature, eyes, skeleton, and brain was completed, and biospecimens were archived. Of 3,370 eligible participants, 2,063 (61%, mean age 71 years) underwent EBCT at first examination (57) . Thus, the Rotterdam Study was an older sample than in MESA or in the HNR study. The median CAC was 98 (25th and 75th percentiles: 10 and 430). Despite age and ethnicity differences between cohorts, findings in the Rotterdam Study for CAC and disease risk have been generally similar to those in MESA and in the HNR study (58) . A strong and graded association was found between coronary calcification and myocardial infarction, and the association remained present, even in older subjects (57, 58) . The CARDIA (Coronary Artery Risk Development in Young Adults) study measured CAC during follow-up and is the first prospective cohort to include data on CAC among subjects from 32 to 46 years of age. Follow-up for atherosclerotic cardiovascular disease events was similar in all 4 studies and included hard endpoints such as myocardial infarction and cardiac death but also, in some studies, included soft endpoints such as coronary revascularization for appropriate clinical indications. *Number with CT scans available for analysis at the baseline examination. †Clinical CAD patients were excluded for this table (7% of the overall HNR study). ‡CAC prevalence differed in different ethnic/racial groups in MESA (50) .
MESA (Multi-Ethnic
CARDIA showed that CAC >0 is not uncommon in this age group, particularly when a risk factor is present (61,62). Over an approximately 10-year follow-up period, CAC strongly predicted risk beyond traditional risk factors in these young subjects (63) .
The Jackson Heart Study measured CAC during follow-up. Among African Americans, CAC predicted risk beyond the traditional risk factors and has been shown to better identify persons most likely to benefit from preventive therapies (64, 65 Heart Association (AHA) guidelines (7, 73) to guide long-term statin therapy among subjects at 
CAC AND PREVENTIVE THERAPIES
Although there is now ample evidence that CAC improves statistical risk reclassification (83, 84) , that is, CAC has also been shown to be an independent predictor of dementia (120) . Ongoing work seeks to clarify the role of CAC in predicting risk for ASCVD versus cancer across the life span (121) . CAC also appears valuable in identifying long-term "healthy agers":
those surviving into old age with CAC ¼ 0 (122).
CAC AND GUIDELINES
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